Abstract
Therapeutic development for Alzheimers disease has largely focused on the removal of beta amyloid because of its suggested role in the primary agent in initiating the disease process. However, with the recent discovery of mutations that result as pathologic buildup of tau in the absence of amyloid pathology, tau is beginning to be recognized as a potential target for drug discovery. We have developed a high-throughput drug screening method that allows for direct intracellular quantitation of tau protein species, enabling the fast, reliable detection of these changes. We have identified a family of small, blood brain barrier penetrant heat shock protein 90 inhibitors that significantly reduce tau protein levels in vitro. Western blot analysis demonstrated a clear inverse correlation between the tau levels and the increase in HSP27, HSP40 and HSP90. Modifications to this assay will further allow the specific analysis of pathologically relevant species. Using this assay, we have demonstrated that a class of HSP90 inhibitors is able to significantly lower intracellular tau levels most likely through induction of a heat shock response.
Keywords: alzheimer, ’, s disease (ad), neurodegeneration, neurofibrillary tangles (nft), nmda receptor antagonist, amyloid precursor protein, tau knockout mice, expression
Current Alzheimer Research
Title: Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Volume: 2 Issue: 2
Author(s): Chad A. Dickey, Jason Eriksen, Adeela Kamal, Francis Burrows, Srinivas Kasibhatla, Christopher B. Eckman, Mike Hutton and Leonard Petrucelli
Affiliation:
Keywords: alzheimer, ’, s disease (ad), neurodegeneration, neurofibrillary tangles (nft), nmda receptor antagonist, amyloid precursor protein, tau knockout mice, expression
Abstract: Therapeutic development for Alzheimers disease has largely focused on the removal of beta amyloid because of its suggested role in the primary agent in initiating the disease process. However, with the recent discovery of mutations that result as pathologic buildup of tau in the absence of amyloid pathology, tau is beginning to be recognized as a potential target for drug discovery. We have developed a high-throughput drug screening method that allows for direct intracellular quantitation of tau protein species, enabling the fast, reliable detection of these changes. We have identified a family of small, blood brain barrier penetrant heat shock protein 90 inhibitors that significantly reduce tau protein levels in vitro. Western blot analysis demonstrated a clear inverse correlation between the tau levels and the increase in HSP27, HSP40 and HSP90. Modifications to this assay will further allow the specific analysis of pathologically relevant species. Using this assay, we have demonstrated that a class of HSP90 inhibitors is able to significantly lower intracellular tau levels most likely through induction of a heat shock response.
Export Options
About this article
Cite this article as:
Dickey A. Chad, Eriksen Jason, Kamal Adeela, Burrows Francis, Kasibhatla Srinivas, Eckman B. Christopher, Hutton Mike and Petrucelli Leonard, Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585927
DOI https://dx.doi.org/10.2174/1567205053585927 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracranial Atherosclerotic Stenosis is Related to Post-stroke Cognitive Impairment: A Cross-sectional Study of Minor Stroke
Current Alzheimer Research Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design Naturalistic Measurement of Sleep in Older Adults with Amnestic Mild Cognitive Impairment: Anxiety Symptoms Do Not Explain Sleep Disturbance
Current Alzheimer Research Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Extracellular Vesicles as Drug Delivery Vehicles for Rheumatoid Arthritis
Current Stem Cell Research & Therapy Oligomers on the Brain: the Emerging Role of Soluble Protein Aggregates in Neurodegeneration.
Protein & Peptide Letters Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry Onset Age and Clinical Heterogeneity of Dementias: A Diagnostic and Therapeutic Approach
Current Psychopharmacology Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review
Current Gene Therapy Density Functional Theory, Molecular Interaction Fields, Pharmacophore, Virtual Screening and Physical Chemistry of the Interactions of Novel Acetylcholinesterase Inhibitors in Alzheimer´s Disease
Current Physical Chemistry Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Effects of Coenzyme Q and Creatine Supplementation on Brain Energy Metabolism in Rats Exposed to Chronic Cerebral Hypoperfusion
Current Alzheimer Research New Anti-Thrombotic Drugs for Stroke Prevention
Current Vascular Pharmacology Involvement of the Serotonergic System in Cognitive and Behavioral Symptoms of Alzheimers Disease
Current Psychiatry Reviews Regulatory Role of Chinese Herbal Medicine in Regulated Neuronal Death
CNS & Neurological Disorders - Drug Targets Involvement of the Septo-Hippocampal Cholinergic Pathway in Association with Septal Acetylcholinesterase Upregulation in a Mouse Model of Tauopathy
Current Alzheimer Research The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology Editorial: Pain in Dementia: A Distressing Combination of Several Factors
Current Alzheimer Research Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research